WESTFORD, Mass., Jan. 13,
2015 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO), which
designs, manufactures and markets medical devices for aesthetic
procedures and precision surgical applications worldwide, today
announced that the Company's independent directors have elected
William O. Flannery as Lead
Director. Flannery, a member of Cynosure's Board of Directors
since June 2013, will continue to
serve on the Compensation and the Nominating and Corporate
Governance committees of the Board.
Flannery's duties as Lead Director will include chairing
meetings of the Company's independent directors, participating in
the setting of meeting agendas, consulting on matters of corporate
governance and Board performance with the Chairman, and
facilitating communications between other members of the Board and
the Chairman. He also will be available, when appropriate, for
consultation and communication with shareholders.
"The appointment of Bill Flannery
as lead director is an important step in demonstrating our
commitment to strong corporate governance," said Chairman and Chief
Executive Officer Michael Davin.
"The lead director's role is to advance the independence of the
board in representing the interests of the shareholders. With his
extensive legal and corporate governance background, Bill is
ideally suited for this responsibility."
Flannery, who served as the Company's Secretary and counsel from
2004 to 2013, has maintained his own legal practice focusing on the
representation of technology-based companies. Since 1993, he also
has served as of counsel to Goulston & Storrs P.C., a
Boston law firm, where he was a
partner from 1992 to 1993. Flannery has served as counsel to and a
director of a number of companies. He was appointed to the Board of
Directors of the Massachusetts Municipal Wholesale Electric Company
by then Governor William Weld and
was subsequently elected Chairman by its members. He was the
general counsel of Thermo Electron Corporation from 1985 to 1992,
and its vice president-administration from 1990 to 1992.
About Cynosure, Inc.
Cynosure develops and markets
aesthetic treatment systems that enable plastic surgeons,
dermatologists and other medical practitioners to perform
non-invasive and minimally invasive procedures to remove hair,
treat vascular and benign pigmented lesions, remove multi-colored
tattoos, revitalize the skin, liquefy and remove unwanted fat
through laser lipolysis, reduce cellulite, clear nails infected by
toe fungus and ablate sweat glands, and improve vaginal health.
Cynosure also markets radiofrequency energy sourced medical devices
for precision surgical applications such as facial plastic and
general surgery, gynecology, ear, nose, and throat procedures,
ophthalmology, oral and maxillofacial surgery, podiatry and
proctology. Cynosure's product portfolio is composed of a broad
range of energy sources including Alexandrite, diode, Nd: YAG,
picosecond, pulse dye, Q-switched lasers, intense pulsed light and
radiofrequency technology. Cynosure sells its products
globally under the Cynosure, Palomar, ConBio and Ellman brand names
through a direct sales force in the
United States, Canada,
Mexico, France, Germany, Spain, the United
Kingdom, Australia,
China, Japan and Korea, and through international
distributors in approximately 120 other countries. For
corporate or product information, visit Cynosure's website at
www.cynosure.com.
Contact:
Scott
Solomon
Vice President
Sharon Merrill Associates, Inc.
617.542.5300
cyno@investorrelations.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cynosure-appoints-william-o-flannery-as-lead-director-300019751.html
SOURCE Cynosure, Inc.